Wed. May 12th, 2021

We have put heart data in your hands: Ira Bahr, Chief Commercial Officer, AliveCorShahid Akhter, editor, ETHealthworld, spoke to Ira Bahr, Chief Commercial Officer, AliveCor to learn about the power of machine learning that is transforming cardiological care for patients and physicians.

How do you see the Indian device market scenario in cardiology?
Cardiovascular diseases claim millions of lives around the world, more than all forms of cancer combined. By many measures, Indians have an even greater propensity than average of cardiovascular disease. So, especially in India, it’s important to not only detect heart conditions, but to help patients manage them as well.

Has AliveCor leveraged technology by way of AI and machine learning to develop the personal ECG?
Yes, our US FDA-cleared personal electrocardiogram (ECG) technology uses AI and machine learning to detect the most common arrhythmias—atrial fibrillation, bradycardia, and tachycardia—with 98% sensitivity and 97% specificity. We have nearly one million users around the world who have recorded over 80 million ECGs to-date. There is a large amount of data contained in an ECG and the ability to extract usable, helpful diagnostic information for patients and physicians alike is something we invest heavily in. We use the power of AI and machine learning to transform cardiological care for people around the world.

Your vision and investment in the Indian market.
Our journey in India is not limited to Indian patients alone. We hope to extend the scope of our product’s impact to Indian physicians and medical institutions. With the burden of cardiovascular disease increasing, our technology is making heart care more accessible, affordable, and convenient than it’s ever been before. We’re excited to continue expanding our global footprint and aim to play a major role in transforming cardiology not only in India, but worldwide.

How do you compare KardiaMobile to any other traditional ECG device and how about clinical validation?
When it comes to clinical validation, KardiaMobile is unmatched. With more than 100 peer-reviewed studies, our personal ECG technology is the most clinically-validated in the world, allowing us to put reliable medical-grade data in the hands of patients and physicians.

Additionally, KardiaMobile allows people to record their ECG anytime, anywhere in just 30 seconds. Traditional in-hospital ECGs require an in-person visit and use of wires, patches, or gels. In some cases, capturing heart events in-hospital is difficult because the patient can’t recreate the symptoms on demand. With KardiaMobile, people can take an ECG from their own home the moment they feel a symptom, recording real-time data right to their smartphone that they can then share with their physician remotely. And with our six-lead device, KardiaMobile 6L, patients and physicians have access to a more detailed view of the heart than a single-lead personal ECG.

How does this device empower the patients in monitoring and understanding their heart rhythm?
KardiaMobile gives patients the ability to take control of their own heart health like never before. With our device, people get an instant ECG analysis—right from their smartphone and in just 30 seconds. No doctor’s visit required. KardiaMobile helps people take a more active role in the management of their heart health and puts the power of digital health in their own hands.

Source link